Size-exclusion chromatography as a multi-attribute method for process and product characterization of adeno-associated virus

Adeno-associated viruses (AAVs) have recently emerged as a leading platform for gene therapy. Due to the complex manufacturing process and structural features of AAVs, extensive process and product characterization studies are required to better understand product quality and batch-to-batch variability. It is, therefore, critical to develop a fast and reliable analytical method to monitor different product quality attributes (PQAs) of AAVs. In this study, we developed a multiple-attribute monitoring (MAM) method for the characterization of AAV PQAs. The MAM method was developed using the separation capability of size-exclusion chromatography (SEC) in connection with multiple in-line detectors: ultraviolet (UV), fluorescence (FLD), multi-angle light scattering (MALS), and refractive index (RI). We demonstrate that our SEC-based MAM method can be used to measure different PQAs, including genome and capsid titer, purity, aggregation, and full/empty capsid ratios in a single assay. Our SEC-based MAM method achieves similar results when compared side by side with orthogonal, individual assays such as quantitative polymerase chain reaction (qPCR), enzyme-linked immunosorbent assay (ELISA), and anion-exchange chromatography (AEX). Moreover, here we demonstrate that a simple, label-free, cost-effective, minimum sample requirement, and a high-throughput method can be applied to support process development, product characterization, release, and stability testing.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Methods & Clinical Development
Published
2024-11-19
DOI
https://doi.org/10.1016/j.omtm.2024.101382
Citations
7
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
3.85

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Size-exclusion chromatography as a multi-attribute method for process and product characterization of adeno-associated virus

Sri Hari Raju Mulagapati, Tomasz M. Witkos, Thomas Linke, Nicholas J. Bond et al.
7 citations
Molecular Therapy — Methods & Clinical Development
Virus-based gene therapy research
3.85
article

Size-exclusion chromatography as a multi-attribute method for process and product characterization of adeno-associated virus

Sri Hari Raju Mulagapati, Tomasz M. Witkos, Thomas Linke, Nicholas J. Bond, Xu Wei, Arun Parupudi, Guoling Xi, Xiaoyu Chen, Albert E. Schmelzer
article en
7 citations

Abstract

Adeno-associated viruses (AAVs) have recently emerged as a leading platform for gene therapy. Due to the complex manufacturing process and structural features of AAVs, extensive process and product characterization studies are required to better understand product quality and batch-to-batch variability. It is, therefore, critical to develop a fast and reliable analytical method to monitor different product quality attributes (PQAs) of AAVs. In this study, we developed a multiple-attribute monitoring (MAM) method for the characterization of AAV PQAs. The MAM method was developed using the separation capability of size-exclusion chromatography (SEC) in connection with multiple in-line detectors: ultraviolet (UV), fluorescence (FLD), multi-angle light scattering (MALS), and refractive index (RI). We demonstrate that our SEC-based MAM method can be used to measure different PQAs, including genome and capsid titer, purity, aggregation, and full/empty capsid ratios in a single assay. Our SEC-based MAM method achieves similar results when compared side by side with orthogonal, individual assays such as quantitative polymerase chain reaction (qPCR), enzyme-linked immunosorbent assay (ELISA), and anion-exchange chromatography (AEX). Moreover, here we demonstrate that a simple, label-free, cost-effective, minimum sample requirement, and a high-throughput method can be applied to support process development, product characterization, release, and stability testing.

Molecular Therapy — Methods & Clinical DevelopmentVol. 32(4)
Center for Veterinary Medicine (US), AstraZeneca (Australia) (AU), Alexion Pharmaceuticals (United States) (US), AstraZeneca (Poland) (PL)
U.S. Department of Defense, Defense Advanced Research Projects Agency, Advanced Research Projects Agency, Defense Sciences Office, DARPA
Reduced inequalities
Openalex Percentile: Top 6%
Virus-based gene therapy research
3.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.